EXECUTIVE ENGAGEMENTS
OUTREACH
372
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
74
Interactions with Platform & by Email
PARTICIPANTS
13
Unique # Participated
VALIDATIONS
6
Responses Validated*
COMPETITORS
46
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
156
PAGES
232
EDITION
9
PRICE
USD 4950
*Engagement stats are ongoing and dynamic
HIGHLIGHTS
Amid the COVID-19 crisis, the global market for Hereditary Angioedema estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$3.9 Billion by 2027, growing at a CAGR of 7.8% over the analysis period 2020-2027. C1 Esterase Inhibitor, one of the segments analyzed in the report, is projected to record a 8.7% CAGR and reach US$2.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Selective Bradykinin B2 Receptor Antagonist segment is readjusted to a revised 6.5% CAGR for the next 7-year period.
The Hereditary Angioedema market in the U.S. is estimated at US$690.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$683.6 Million by the year 2027 trailing a CAGR of 7.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.3% and 6.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.
In the global Kallikrein Inhibitor segment, USA, Canada, Japan, China and Europe will drive the 7.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$89.6 Million in the year 2020 will reach a projected size of US$149.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$451.7 Million by the year 2027.
SELECT PLAYERS
BioCryst Pharmaceuticals, Inc.; CSL Ltd.; iBio, Inc.; Ionis Pharmaceuticals, Inc.; Pharming Group NV; Shire PLC
SEGMENTS
» Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels) » Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes) » Route of Administration (Intravenous, Subcutaneous Injection, Oral)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Hereditary Angioedema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hereditary Angioedema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hereditary Angioedema by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for C1 Esterase Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for C1 Esterase Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for C1 Esterase Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Selective Bradykinin B2 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Selective Bradykinin B2 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Selective Bradykinin B2 Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Kallikrein Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Kallikrein Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Kallikrein Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Subcutaneous injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Subcutaneous injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Subcutaneous injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hospital pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hospital pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hospital pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Retail pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Retail pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Retail pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Hereditary Angioedema by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Hereditary Angioedema by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Hereditary Angioedema by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 46 |
The U.S. Economy is Reinventing Itself to Weather Economic Storms.
Here's An Analytical Window into the Changing Opportunities.
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com